Current pharmacotherapeutic strategies for overactive bladder (Q34706864)

4 August 2017

1 reference

title

Current pharmacotherapeutic strategies for overactive bladder (English)

1 reference

4 August 2017

Alan D Garely

1

1 reference

4 August 2017

Lara J Burrows

series ordinal

2

1 reference

4 August 2017

language of work or name

English

0 references

publication date

1 July 2002

1 reference

Expert Opinion on Pharmacotherapy

4 August 2017

published in

1 reference

4 August 2017

volume

3

1 reference

4 August 2017

issue

7

1 reference

4 August 2017

page(s)

827-833

1 reference

Pharmacological agents for the treatment of urinary incontinence due to overactive bladder

4 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1517%2F14656566.3.7.827

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.3.7.827

Muscarinic receptor antagonists in the treatment of overactive bladder

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.3.7.827

An extended-release formulation of oxybutynin chloride for the treatment of overactive urinary bladder

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.3.7.827

Extended-release oxybutynin

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.3.7.827

Urodynamic and other effects of tolterodine: a novel antimuscarinic drug for the treatment of detrusor overactivity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.3.7.827

Twelve-month treatment of overactive bladder: efficacy and tolerability of tolterodine

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.3.7.827

Treatment of overactive bladder: long-term tolerability and efficacy of tolterodine

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.3.7.827

Tolterodine once-daily: superior efficacy and tolerability in the treatment of the overactive bladder.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.3.7.827

A comparison of the effects on saliva output of oxybutynin chloride and tolterodine tartrate

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.3.7.827

Efficacy, tolerability and safety profile of propiverine in the treatment of the overactive bladder (non-neurogenic and neurogenic).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.3.7.827

Double-blind study of imipramine and placebo for incontinence due to bladder instability

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.3.7.827

Intravesical capsaicin and resiniferatoxin therapy: spicing up the ways to treat the overactive bladder

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.3.7.827

Enhancing patient compliance in the elderly. Role of packaging aids and monitoring

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.3.7.827

Tolterodine, a new antimuscarinic drug for treatment of bladder overactivity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.3.7.827

21 January 2018

Identifiers

DOI

10.1517/14656566.3.7.827

1 reference

4 August 2017

1 reference